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DOI 10.1016/j.chembiol.2010.01.005Tobacco has been used for centuries
despite its health risks. Cigarettes are
hard to quit because they deliver nicotine,
a potent and addictive drug, along with
‘‘tar.’’ But now nicotine is angling for
redemption in the form of a new class of
CNS drugs targeting neuronal nicotinic
receptors (NNRs) also known as neu-
ronal acetylcholine nicotinic receptors
(nAChRs), which modulate the flow of
neurotransmitters throughout the brain
and nervous system.
Tobacco companies have long capital-
ized on the addictive properties of nico-
tine, but the future boom may come
from biotechs like Targacept (http://
www.targacept.com) and their pharma-
ceutical company partners. Enriched
with a dowry of 450 research patentsIf we can pull the nicotinic treatment away from the tobacco
addiction, we can open the way to useful therapeutics.from tobacco company R.J. Reynolds,
Winston-Salem, North Carolina-based
Targacept is developing NNR-targeting
drugs to treat conditions like major
depression, adult attention deficit hyper-
activity disorder (ADHD), Parkinson’s
disease, cognitive dysfunction in schizo-
phrenia, and, of course, smoking cessa-
tion. Targacept, now public, was spun off
from R.J. Reynolds in 1997.
Targacept has collaborations with
AstraZeneca and GlaxoSmithKline, but
other large pharmaceutical companies
also have NNR discovery programs.
Pfizer launched the first NNR drug, vareni-
cline (Chantix), for smoking cessation in
2006. Danish biotech NeuroSearch
(http://www.neurosearch.com) has code-
veloped Abbotts’ NNR compounds: ABT-
894 for ADHD and ABT-560 for cognitive
dysfunction. Roche has a single NNR
drug, RG3487 (formerly MEM3454),
which is a nicotinic a7 receptor agonist
for Alzheimer’s/schizophrenia that is cur-
rently in phase 2 trials. RG3487 was
acquired by Roche from Montvale, NewJersey-based Memory Pharmaceuticals,
which Roche purchased in 2009.
I’ll Have My Nicotine Straight Up,
Thank You
NNRs are pentameric ligand-gated ion
channels composed of five protein
subunits containing binding sites for
acetylcholine and other neurotransmit-
ters. These receptors are activated by
nicotine as well. NNRs are widespread in
the central nervous system, autonomic
nervous system, and skeletal muscles.
Nicotinic receptor research is over a
century old, but it is only in the last
20 years that it became evident that these
receptors were also abundant in the brain.
Researchers started becoming aware of
nicotine’s positive effects and developingNNR agonists to treat cognitive function
in the early 1990s.
‘‘There is much comorbidity between
tobacco smoking and psychiatry disor-
ders, probably because people attempt
to self-medicate symptoms of psychiatric
disorders with the nicotine contained in
tobacco,’’ said Athina Markou, Ph.D.,
Professor, Department of Psychiatry,
Schoolof Medicine, University of California
at San Diego. According to Markou,
studies estimate that people with mental
illness smoke at a much higher rate than
the general population. Almost 90% of
schizophrenics smoke and half of the
people with depression smoke, compared
to between 13% and 22% of the general
population.
‘‘Schizophrenia patients have cognitive
deficits,’’ said Markou. ‘‘The cognitive
deficits that you see in Alzheimer’s or in
dementia or in other disorders may have
the same neurobiological substrates as
the cognitive deficits that you see in
schizophrenia.’’ According to Markou,
perhaps a single compound that activatesChemistry & Biology 17, January 29, 20specific nicotinic acetylcholine receptors
in a particular brain site could be used to
treat a variety of cognitive deficits in
various disorders. This may be possible
because the neuronal mechanisms that
mediate a cognitive deficit in attention,
for example, may be the same.
According to Edward D. Levin, Ph.D.
Professor of Psychiatry, Duke University
Medical Center, and Targacept collabo-
rator, multiple studies have shown that
administering nicotine via skin patches
can improve cognitive functions such as
attention and memory. ‘‘Nicotine can be
deadly in promoting tobacco addiction,
but there is also a possible benefit,’’ said
Levin. ‘‘Part of the brakes on the field
has been the demonization of nicotine. I
think if we can pull the nicotinic treatment
away from the tobacco addiction, we can
open the way to useful therapeutics.’’
But patches delivering a low dose of
nicotine over a long period of time can
profoundly desensitize receptors, accord-
ing to Marina Picciotto, Ph.D, Professor of
Psychiatry, Yale University. According to
Picciotto, one of the puzzles of the nico-
tine literature is determining what effects
of nicotine are due to activation and/or
inactivation of receptors or a combination
thereof.
‘‘Nicotinic receptors are modulators,’’
said Picciotto. ‘‘They are not like glutamate
receptors or GABA receptors where they
turn on or shut down a neuron. What that
means is that they are extremely sensitive
to the starting conditions of the system.’’
According to Picciotto, introducing nico-
tine or a nicotinic agonist to highly active
neurons will likely decrease their activity
through increasing the release of GABA.
Conversely, an agonist would accelerate
the firing rate of silent neurons both by
local depolarization as well as increasing
release of more excitatory neurotransmit-
ters. In an aberrant state of circuit level
dysregulation, nicotinic receptors are
extremely good at getting a system back
to the mean. ‘‘It is your brain that gives
you some of the specificity of the drug,
not only the actual subtypes of the10 ª2010 Elsevier Ltd All rights reserved 1
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vidual neuron.’’ said Picciotto.
Modulating Mood
In some neuropsychiatric disorders, nico-
tinic receptor groups are lost or missing,
according to Dr. Merouane Bencherif,
Vice President, Preclinical Research at
Targacept. One theory is that Alzheimer’s
patients lose certain NNRs and the
neurons that contain them, which is why
they slide into dementia. Schizophrenics
have genetic abnormalities in receptors
that cause difficulty in sensory gating
and processing information. In Parkin-
son’s patients’ brains, certain receptors
die, causing motor control problems. Inci-
dentally, epidemiological data shows that
smoking strikingly reduces the risk of
developing Parkinson’s disease.
According to Bencherif, NNRs nor-
malize the neurotransmitter tone in the
brain. There are diverse subtypes of
NNRs. ‘‘This is very important for our
company, because we go and target
specific receptors and we don’t interact
with the receptors in the heart or ganglia
so we don’t have the side effects,’’ said
Bencherif. (That’s why most drug develop-
ment focuses on eliminating the effects on
a3/b4 receptors that are highly expressed
in ganglia, to avoidactivation of the periph-
eral nicotinic receptors in end organs and
the autonomic nervous system.)
Targacept Pipeline
Targacept’s lead small molecule
compound is TC-5214, a drug for major
depression that modulates the a4/b2
NNR subtype. TC-5214 is the (S) (+)
enantiomer of mecamylamine hydrochlo-
ride, a nicotinic channel blocker. About
14.8 million Americans suffer from major
depression (and about 44 million world-
wide); the most frequently prescribed
drugs, selective serotonin reuptake inhib-
itors (SSRIs), only work in about 60% of
patients.
According to Bencherif, one hypothesis
is that depression is due to too much
acetylcholine being released in the brain.
TC-5214 completed a phase 2b trial this
year as adjunctive therapy for nonre-
sponders to SSRI drugs. While the results
have not been replicated by other groups,
AstraZeneca agreed to take it further
in a collaboration worth potentially $1.34
billion if all scientific and sales milestones
are met.2 Chemistry & Biology 17, January 29, 2010 ªTargacept’s phase 2 compound TC-
1734 (now AZD 3483) for adult ADHD is
a small molecule agonist for one or more
forms of a4/b2 NNR. About 5 to 8 million
adults in the U.S. have ADHD as well as
over 12 million children. ADHD symptoms
are generally treated with stimulants and
sometimes antidepressants. But stimu-
lants are addictive, raise blood pressure,
and can cause serious cardiovascular
problems. In July 2009, AstraZeneca
announced continued development in a
collaboration worth up to $100 million, if
milestones are met, and made a milestone
payment of $10 million. According to
Bencherif, AZD 3483 works upstream
from synapses, enhancing activity in
certain areas of the brain, and seems to
have placebo-like side effects.
Targacept’s phase 1 drug TC-6683
(AZD 3483) for Alzheimer’s disease is an
agonist of one or more forms of a4/b2
NNR. ‘‘The drug seems to help retain
receptor viability,’’ said Bencherif. ‘‘We
are counting on this property to try to
decrease, inhibit, or stop the neural degen-
eration seen in Alzheimer’s disease.’’
TC-5619 for cognitive impairment in
schizophrenia has initiated a phase 2 clin-
ical proof-of-concept trial. TC-5685 in
phase 1 for depression and anxiety disor-
ders inhibits activity of one or more forms
of the a4/b2 NNR. Targacept also has a
global alliance with GlaxoSmithKline for
five NNR preclinical compounds.
Getting Booted from the Mile-High
Club
In July 2009, the FDA slapped varenicline
(Chantix), a partial agonist a4/b2 NNR
smoking cessation drug, and bupropion
(Zyban), a competing drug, with a black
box warning. Both had been banned for
use by pilots and air traffic controllers
the previous year because, out of 6 million
plus prescriptions written, a few hundred
people had suicidal thoughts and some
acted upon them. The FDA noted that
while people with underlying psychiatric
conditions should not take these drugs,
not all people who experienced symp-
toms had a psychiatric history. On the
other hand, nicotine withdrawal can
precipitate depression.
‘‘Existing NNR drugs are not very selec-
tive compounds,’’ commented Daniel
Timmermann, Ph.D., Vice President,
Director of CNS Pharmacology, Neuro-
Search. ‘‘What we are trying to do at2010 Elsevier Ltd All rights reservedNeuroSearch is to create very selective
compounds.’’ NeuroSearch and Abbott’s
two NNR compounds for ADHD in phase
2 and for cognitive function in phase 1
stemmed from a 5 year collaboration
between the two companies, with Abbott
responsible for the clinical development
under a license agreement.
NeuroSearch/Abbott’s ADHD com-
pound is a full agonist of a4/b2. ‘‘At
a very basic level, you can say that what
we believe to be the mechanism of action
of NNR modulation in ADHD is partly
based on the ability of the NNR agonist
to enhance dopaminergic and noradren-
ergic transmissions in the basal fore-
brain,’’ said Timmermann.
According to Timmermann, neurotrans-
missionbasedon these transmittersystems
is aberrant in the basal forebrain in ADHD
patients. By enhancing these neurotrans-
mitters, NNR selective compounds can
correct the imbalance as well as augment
cognitive function. ‘‘There isahostofclinical
studies deriving from many years back that
uniformly show agents capable ofactivating
nicotinic receptors, namely the a4/b2
subtype, are good for enhancing attention,’’
said Timmermann.
Targacept’s ADHD AZD-3480 drug
has a mechanism of action comparable
to ABT-894, noted Timmermann. Neuro-
Search’s NNR compound ABT-560 also
targets a4/b2 receptors. The company’s
earlier stage NNR drug candidates target
a7, the second most common type of
NNR receptor found in the mammalian
brain, which is also associated with cogni-
tive function.
While patients have been dosed in clin-
ical studies lasting several weeks or
months, the effectsof long-termuse remain
unknown. ‘‘This has been a conundrum
in nicotinic receptor research for many
years: how can you activate these recep-
tors permanently with agonists when you
know from various cell-based systems
that these receptors are prone to become
desensitized upon prolonged exposure to
agonists,’’ Timmermann said. ‘‘To tell you
the truth, there is really not a uniform solu-
tion to that problem. However, it does
appear to be dose dependent. There has
really been a highly competitive race in
last 5 years to see who would reach the
clinic first with some of these compounds.’’Wendy Wolfson is a science and technology writer
based in the Bay Area. wendywolfson@nasw.org
